Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised the Port of Gothenburg in conjunction with the transfer of the car terminal
Mandate

Vinge advised the Port of Gothenburg in conjunction with the transfer of the car terminal

February 17, 2011

As a part of the ongoing privatisation of the terminal operations in the Port of Gothenburg, the car terminal has been transferred to Logent AB. At the same time, a 10-year licence agreement has been entered into between the parties regarding utilisation of the terminal and related infrastructure. The Port of Gothenburg is the largest port in the Nordic region and a focal point for the Swedish car industry. Logent AB is a Swedish company with approximately 1000 employees which conducts ports, combined terminals and warehousing operations in Sweden and Norway. Vinge advised the Port of Gothenburg Harbour during the privatisation procedure.
Vinge’s team consisted of, among others, Fredrik Sonander, Charlotte Johansson and Lisa Askbrink.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026